August 1968

Phosphate Supplementation as an Adjunct in the Therapy of Multiple Myeloma

Author Affiliations


From the Thorndike Memorial Laboratory, Second and Fourth (Harvard) Medical Services, Boston City Hospital, and the Department of Medicine, Harvard Medical School (Drs. Goldsmith, Hulley, and Ingbar), and the Tufts Hematology Laboratory, Boston City Hospital, and the Department of Medicine, Tufts University Medical School (Drs. Bartos and; Moloney), Boston. Dr. Goldsmith is recipient of the NIH Career Development Award. Dr. Bartos is now at the Department of Medicine, State University of New York, Upstate Medical Center, Syracuse, NY. Dr. Moloney is now at the Department of Medicine, Peter Bent Brigham Hospital, and Harvard Medical School, Boston.

Arch Intern Med. 1968;122(2):128-133. doi:10.1001/archinte.1968.00300070032006

Fourteen patients with multiple myeloma have been treated with phosphate supplements given orally or intravenously. In all of the seven patients with hypercalcemia, serum calcium was reduced into the normal range and maintained at that level as long as phosphate supplementation was continued. Hypercalciuria was likewise reduced by administration of phosphate, even in the absence of hypercalcemia. All patients experienced some relief of pain, and five became symptom-free. No significant complications of phosphate supplementation were observed.